Manufacturing

Articles

In a recently released statement, FDA Commissioner Scott Gottlieb warned of an amino acids supply shortage and gave an update on a saline supply shortage, both due to the impact of hurricanes on Puerto Rican manufacturing facilities.

FDA Warns of Amino Acid Shortage Due to Hurricane Maria

The acquisition gives GE Healthcare access to a nanofiber-based platform purification technology that can offer improvements in biopharmaceutical productivity.

GE Healthcare Completes Acquisition of Bioprocessing Start-Up

As part of the deal, J&J’s Janssen will pay an upfront payment of $50 million to research, develop, and commercialize up to six bispecific antibodies.

J&J and Zymeworks in Bispecific Antibody Pact Worth Nearly $1.5 Billion

Bayer will make a $400-million upfront payment to develop and commercialize two anti-cancer compounds in Loxo Oncology’s portfolio.

Bayer in $1.5-Billion Deal with Loxo Oncology for Anti-Cancer Drugs

The company’s new modules offer scalable single-pass diafiltration and were exclusively showcased during its Leadership Forum series in Westborough, MA.

Pall Debuts New Inline Diafiltration Modules for Continuous Bioprocessing

The use of therapeutic vaccines presents a new way to manage diseases, such as cancer and sexually transmitted diseases.

Therapeutic Vaccines Target Cancer and Other Viral-Induced Diseases

LeonardMestrandrea is principal of Mestrandrea Consulting LLC.

James P. Agalloco is the president of Agalloco & Associates, P.O. Box 899, Belle Mead, NJ 08502, tel. 908.874.7558, jagalloco@aol.com. He is also a member of Pharmaceutical Technology’s editorial advisory board.

Alternatives to time-consuming, error-prone operations promise to reduce vaccine manufacturing costs and improve facility flexibility.

Moving to Closed Systems for Aseptic Processing

The company has officially opened a local brand office in South Korean to support its existing business in the region.

Vetter Expands in Asia-Pacific

The $72-million investment, part of a larger $850-million investment into its US operations, will allow the drugmaker to replace an outdated insulin vial-filling line and to upgrade technology at its Indianapolis manufacturing plant.

Lilly to Invest $72 Million for Insulin Manufacturing Upgrade

The company is investing EUR 170 million (US$201 million) to expand its vaccine manufacturing site in France for its newest influenza vaccine.

Manufacturing, Parenterals and Injectables